The study therapy, CMN-001, is designed to work with standard cancer therapies to help your immune system fight kidney cancer. Here is how it’s made:
Adding your tumor information to your blood cells may help your immune system more effectively target cancer cells. All participants will also receive FDA-approved, standard therapies for advanced kidney cancer, or renal cell carcinoma (RCC).
Investigational medicines are not approved as standard medical care. They can only be used in clinical research studies until authorities, like the US Food and Drug Administration (FDA), deem them safe and effective for people.
Prior studies with CMN-001
CMN-001 has been previously tested in many cancer patients and has been found to be safe.